Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety.
Level 5 - mechanism / opinion, no new human data
Narrative review and conference proceeding overview without systematic methodology or primary human trial data.
PubMed 12901025 · doi:10.1093/ajhp/60.suppl_2.S9
What was done
This conference proceeding narrative review summarized the dissolution, pharmacokinetics, efficacy, and safety profiles of immediate-release (IR), sustained-release (SR), and extended-release (ER) niacin formulations used in the management of dyslipidemia.
What was found
No quantitative data, sample sizes, or effect estimates were reported in the abstract. Niacin was qualitatively described as increasing high-density lipoprotein cholesterol and decreasing total cholesterol, low-density lipoprotein cholesterol, lipoprotein(a), and triglycerides. The abstract notes that cutaneous flushing is associated with IR niacin and hepatotoxicity with SR niacin, while intermediate-dissolution ER niacin demonstrates lower flushing rates than IR and lower hepatotoxic potential than SR.
Why it matters
Different release rates alter metabolite formation, allowing clinicians to optimize product selection by balancing adherence limitations from flushing against risks of hepatotoxicity.
Limits
The abstract contains no primary data, statistical comparisons, or formal systematic review methodology. It relies on generalized narrative synthesis.
Cited by
- supports In published literature, liver toxicity from niacin is associated with time-released formulations rather than immediate-release free niacin.